PUBLISHER: The Business Research Company | PRODUCT CODE: 1713492
PUBLISHER: The Business Research Company | PRODUCT CODE: 1713492
Animal gastroesophageal reflux disease (GERD) occurs when stomach acid or bile flows back into the esophagus, leading to irritation and inflammation. This condition can cause symptoms such as vomiting, regurgitation, weight loss, and discomfort during eating. Diagnosing and treating GERD in animals aims to relieve discomfort, enhance quality of life, and prevent complications such as esophagitis, ulcers, or strictures.
The main product types for managing animal GERD include treatment and diagnostic options. Treatment involves products designed to manage and alleviate GERD symptoms in animals, such as antacids, proton pump inhibitors, and other medications that reduce stomach acid and support digestive health. These treatments are available in over-the-counter (OTC) and prescription forms, with administration routes including oral and injectable. GERD treatments are used for both companion animals and livestock. Distribution channels for these products include veterinary hospitals and clinics, retail pharmacies, and e-commerce platforms.
The animal gastroesophageal reflux disease market research report is one of a series of new reports from the business research company that provides animal gastroesophageal reflux disease market statistics, including animal gastroesophageal reflux disease industry global market size, regional shares, competitors with an animal gastroesophageal reflux disease market share, detailed animal gastroesophageal reflux disease market segments, market trends and opportunities, and any further data you may need to thrive in the animal gastroesophageal reflux disease industry. This animal gastroesophageal reflux disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The animal gastroesophageal reflux disease market size has grown strongly in recent years. It will grow from $1.82 billion in 2024 to $1.98 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to an increase in pet obesity rates, advances in veterinary diagnostic technologies, growing awareness of gastrointestinal disorders in pets, improved veterinary care and treatment options, increased pet ownership and expenditure on pet health, and the and the development of specialized veterinary pharmaceuticals and diets.
The animal gastroesophageal reflux disease market size is expected to see strong growth in the next few years. It will grow to $2.76 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to rising prevalence of gastrointestinal disorders in pets, growing demand for advanced diagnostic and treatment options, increasing awareness and education about pet health, expanding pet insurance coverage and veterinary services, advancements in veterinary pharmaceuticals and treatments, rising disposable incomes, and willingness to spend on pet health. Major trends in the forecast period include specialized and personalized treatment options, adoption of advanced diagnostic tools and technologies, veterinary practices and services, preventive care and dietary management, and collaboration between veterinary professionals and pet owners.
The rising humanization of pets is anticipated to drive the growth of the animal gastroesophageal reflux disease (GERD) market. This trend, where pet owners increasingly treat their pets such as human family members and ascribe human-like emotions and needs to them, is fueled by deeper emotional bonds between owners and their pets. As pets are integrated more into family life, there is a heightened demand for specialized healthcare, premium diets, and wellness products that align with human standards. This increased focus on pet health, including conditions such as gastroesophageal reflux disease (GERD), leads to greater demand for veterinary care, diagnostics, treatments, and preventive measures. For example, in April 2024, the American Pet Products Association reported that 86.9 million households in the US had pets in 2023-2024, representing 66% of households, up from 62% in 2022. Thus, the humanization of pets is boosting the growth of the animal GERD market.
Companies in the animal GERD market are focusing on developing specialized diets to support gastrointestinal health and manage GERD symptoms in pets. These gastrointestinal support diets are tailored pet foods designed to alleviate symptoms of gastrointestinal disorders, featuring easily digestible ingredients, balanced nutrients, and added fibers or probiotics for optimal digestive health. For instance, in April 2024, Royal Canin USA, a subsidiary of Mars Incorporated, expanded its veterinary gastrointestinal (GI) range with five new diets aimed at enhancing pet digestive health. These diets, developed with input from researchers and veterinarians, address GI issues in both dogs and cats, including food-responsive sensitivities and fat-restricted needs. New offerings include gastrointestinal low-fat, hydrolyzed protein canine, and gastrointestinal hydrolyzed protein feline, all crafted with highly digestible ingredients to support long-term gastrointestinal health.
In August 2022, CHW Acquisition Corporation (CHW), a US-based investment firm, merged with Wag Labs Inc. for $350 million. This merger allows Wag to leverage its strengthened financial position to expand its subscription services, enhance its technology platform, and broaden its pet care offerings. Wag Labs Inc. provides guidance and solutions for treating animal GERD.
Major companies operating in the animal gastroesophageal reflux disease market are Zoetis Inc., VCA Animal Hospitals, Petco Health and Wellness Company Inc., Merck Animal Health, Boehringer Ingelheim Animal Health, Elanco Animal Health Incorporated, Hill's Pet Nutrition Inc., IDEXX Laboratories Inc., Ceva Sante Animale, Virbac S.A., Phibro Animal Health Corporation, Dechra Pharmaceuticals PLC, Blue Buffalo Company Ltd., Vetoquinol S.A., Antech Diagnostics, Heska Corporation, WellPet LLC, McNeil Consumer Pharmaceuticals Co., Wag Labs Inc. , VetPartners Limited, BioZyme Inc., Zomedica Corp., NexGen Pharmaceuticals LLC
North America was the largest region in the animal gastroesophageal reflux disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the animal gastroesophageal reflux disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the animal gastroesophageal reflux disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The animal gastroesophageal reflux disease market consists of revenues earned by entities by providing services such as specialized veterinary care, prescription medications, diagnostic testing and nutritional counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The animal gastroesophageal reflux disease market also includes sales of gastrointestinal support diets, medications and hydrolyzed protein diets. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Animal Gastroesophageal Reflux Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on animal gastroesophageal reflux disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for animal gastroesophageal reflux disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The animal gastroesophageal reflux disease market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.